Integrated Molecular Medicine for Neuronal and Neoplastic Disorders Volume 1086 published November 2006 Ann. N.Y. Acad. Sci. 1086: 35–53 (2006). doi: 10.1196/annals.1377.005 Copyright © 2006 by the New York Academy of Sciences description | purchase this volume

This Volume Table of Contents Description This Article Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BU, G. Articles by ZERBINATTI, C. Search for Related Content PubMed PubMed Citation Articles by BU, G. Articles by ZERBINATTI, C.

Part II. Alzheimer's Disease and Related Neurodegenerative Disorders

LRP in Amyloid- Production and Metabolism

Key Words: LDL receptor • LRP • LRP1B • APP • A • Alzheimer's disease

Amyloid- peptide (A) production and accumulation in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Recent studies have shown that apolipoprotein E (apoE) receptors, members of the low-density lipoprotein receptor (LDLR) family, modulate A production as well as A cellular uptake. A is derived from proteolytic processing of the amyloid precursor protein (APP), which interacts with several members of the LDLR family. Studies from our laboratory have focused on two members of the LDLR family, the LDLR-related protein (LRP) and LRP1B. Our in vitro studies have shown that while LRP's rapid endocytosis facilitates APP endocytic trafficking and processing to A, LRP1B's slow endocytosis inhibits these processes. In addition to modulating APP endocytic trafficking, LRP's rapid endocytosis also facilitates A cellular uptake by binding to A either directly or via LRP ligands such as apoE. Our in vivo studies using transgenic mice have shown that overexpression of LRP in central nervous system (CNS) neurons increases soluble brain A and this increase correlates with deficits in memory. Together our studies demonstrate that members of the LDLR family modulate APP processing and A metabolism by several independent mechanisms. Understanding the pathways that modulate brain A metabolism may enable the rational design of molecular medicine to treat AD.

This article has been cited by other articles:

				A. M. Martin, C. Kuhlmann, S. Trossbach, S. Jaeger, E. Waldron, A. Roebroek, H. J. Luhmann, A. Laatsch, S. Weggen, V. Lessmann, et al. The Functional Role of the Second NPXY Motif of the LRP1 {beta}-Chain in Tissue-type Plasminogen Activator-mediated Activation of N-Methyl-D-aspartate Receptors J. Biol. Chem., May 2, 2008; 283(18): 12004 - 12013. [Abstract] [Full Text] [PDF]

				M. M.M. Wilhelmus, I. Otte-Holler, J. J.J. van Triel, R. Veerhuis, M. L.C. Maat-Schieman, G. Bu, R. M.W. de Waal, and M. M. Verbeek Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- -Mediated Cell Death of Cerebrovascular Cells Am. J. Pathol., December 1, 2007; 171(6): 1989 - 1999. [Abstract] [Full Text] [PDF]

				G. R Seabrook, W. J. Ray, M. Shearman, and M. Hutton BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics Mol. Interv., October 1, 2007; 7(5): 261 - 270. [Abstract] [Full Text] [PDF]

				M. S. Wolfe and S. Y. Guenette APP at a glance J. Cell Sci., September 15, 2007; 120(18): 3157 - 3161. [Full Text] [PDF]

©2006 New York Academy of Sciences, all rights reserved.
Privacy Policy and Disclaimer.

7 World Trade Center, 250 Greenwich St, 40th Fl, New York, NY 10007-2157
info{at}nyas.org | 212.298.8600